## Eloisa Bonfa

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2643740/publications.pdf

Version: 2024-02-01

420 papers

13,351 citations

<sup>26630</sup>
56
h-index

90 g-index

442 all docs

442 docs citations

times ranked

442

11702 citing authors

#	Article	IF	CITATIONS
1	Let's Talk About Lupus. Overview of an Innovative, High-Reach, Online Program to Fill the Education Gaps of Latin Americans Living With Lupus. Journal of Clinical Rheumatology, 2022, 28, e368-e374.	0.9	17
2	Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. Rheumatology, 2022, 61, 3351-3361.	1.9	13
3	Impact of Distinct Therapies on Antibody Response to <scp>SARSâ€CoV</scp> â€2 Vaccine in Systemic Lupus Erythematosus. Arthritis Care and Research, 2022, 74, 562-571.	3.4	25
4	2019-EULAR/ACR classification criteria domains at diagnosis: predictive factors of long-term damage in systemic lupus erythematosus. Clinical Rheumatology, 2022, 41, 1079-1085.	2.2	7
5	Controversies in Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2022, 28, e651-e658.	0.9	1
6	Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet Rheumatology, The, 2022, 4, e113-e124.	3.9	24
7	Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases. Brain, Behavior, and Immunity, 2022, 101, 49-56.	4.1	18
8	Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases. Vaccine: X, 2022, 10, 100131.	2.1	3
9	Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 710-719.	0.9	16
10	Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients. Journal of Applied Physiology, 2022, 132, 682-688.	<b>2.</b> 5	2
11	Chronic inflammatory diseases, subclinical atherosclerosis, and cardiovascular diseases: Design, objectives, and baseline characteristics of a prospective case-cohort study â€' ELSA-Brasil. Clinics, 2022, 77, 100013.	1.5	1
12	Lifestyle Interventions and Weight Management in Systemic Lupus Erythematosus Patients: A Systematic Literature Review and Metanalysis. Journal of Lifestyle Medicine, 2022, 12, 37-46.	0.8	4
13	Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity. Clinical Rheumatology, 2022, 41, 2079-2089.	2.2	7
14	Hydroxychloroquine increased cholesterol transfer to high-density lipoprotein in systemic lupus erythematosus: A possible mechanism for the reversal of atherosclerosis in the disease. Lupus, 2022, 31, 659-665.	1.6	3
15	Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 1036-1043.	0.9	30
16	Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study. Lancet HIV, the, 2022, 9, e323-e331.	4.7	36
17	Adherence to non-pharmacological preventive measures among healthcare workers in a middle-income country during the first year of the COVID-19 pandemic: Hospital and community setting. American Journal of Infection Control, 2022, 50, 707-711.	2.3	4
18	Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis. Lupus, 2022, 31, 97-104.	1.6	9

#	Article	IF	CITATIONS
19	SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. Rheumatology, 2022, 61, SI169-SI174.	1.9	9
20	Gathering patients and rheumatologists' perceptions to improve outcomes in idiopathic inflammatory myopathies. Clinics, 2022, 77, 100031.	1.5	2
21	Hormone therapy effect on menopausal systemic lupus erythematosus patients: a systematic review. Climacteric, 2022, , 1-7.	2.4	4
22	Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. Annals of the Rheumatic Diseases, 2022, 81, 889-897.	0.9	42
23	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. Lancet Rheumatology, The, 2022, 4, e441-e449.	3.9	17
24	Palliative care in the COVID-19 pandemic: Strategy of HCFMUSP. Clinics, 2022, 77, 100050.	1.5	0
25	Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome. Lupus, 2022, 31, 974-984.	1.6	13
26	Physical activity and antibody persistence 6 months after the second dose of <scp>CoronaVac</scp> in immunocompromised patients. Scandinavian Journal of Medicine and Science in Sports, 2022, 32, 1510-1515.	2.9	2
27	Short- and Long-Term Outcome of Systemic Lupus Erythematosus Peripheral Neuropathy. Journal of Clinical Rheumatology, 2021, 27, S212-S216.	0.9	10
28	Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment. Journal of Clinical Rheumatology, 2021, 27, 248-259.	0.9	18
29	How COVID-19 is changing rheumatology clinical practice. Nature Reviews Rheumatology, 2021, 17, 11-15.	8.0	25
30	A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group. Lupus, 2021, 30, 630-640.	1.6	2
31	The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients. Lupus, 2021, 30, 554-559.	1.6	14
32	UHPLC-MS/MS Method for Determination of Hydroxychloroquine and Its Main Metabolites in Oral Fluid and Whole Blood for Therapeutic Drug Monitoring. journal of applied laboratory medicine, The, 2021, 6, 868-880.	1.3	2
33	Gaps on rheumatologists' knowledge of physical activity. Clinical Rheumatology, 2021, 40, 2907-2911.	2.2	2
34	Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2–3 mg/kg/day): 12-month prospective randomized controlled trial. Clinical Rheumatology, 2021, 40, 2745-2751.	2.2	8
35	Adrenal steroidogenesis and ovarian reserve in adult childhood-onset systemic lupus erytematosus patients. Clinical Rheumatology, 2021, 40, 3651-3658.	2.2	3
36	One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels. Lupus, 2021, 30, 956-964.	1.6	3

#	Article	IF	CITATIONS
37	POS1252â€COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES ON CHRONIC USE OF HYDROXYCHLOROQUIN A LARGE BRAZILIAN COHORT – A 24-WEEK PROSPECTIVE STUDY. Annals of the Rheumatic Diseases, 2021, 80, 909-910.	IE IN 0.9	0
38	Post-acute sequelae of SARS-CoV-2 infection (PASC): a protocol for a multidisciplinary prospective observational evaluation of a cohort of patients surviving hospitalisation in Sao Paulo, Brazil. BMJ Open, 2021, 11, e051706.	1.9	23
39	Factors associated with neuropsychiatric involvement in Latin American patients with systemic lupus erythematosus. Lupus, 2021, 30, 096120332110203.	1.6	0
40	Avoiding misclassification of thrombotic primary antiphospholipid syndrome as systemic lupus erythematosus (SLE): What are the best-performing SLE classification criteria?. Lupus, 2021, 30, 1732-1738.	1.6	5
41	An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Paediatric Drugs, 2021, 23, 331-347.	3.1	49
42	Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nature Medicine, 2021, 27, 1744-1751.	30.7	148
43	Poor Prognosis of COVIDâ€19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Crossâ€5ectional Population Study Of 252 119 Patients. ACR Open Rheumatology, 2021, 3, 804-811.	2.1	20
44	Performance of alpha-defensin lateral flow test after synovial fluid centrifugation for diagnosis of periprosthetic knee infection. World Journal of Orthopedics, 2021, 12, 565-574.	1.8	4
45	Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity. Lupus, 2021, 30, 1915-1922.	1.6	3
46	The new 2019-EULAR/ACR classification criteria specific domains at diagnosis can predict damage accrual in 670 childhood-onset systemic lupus erythematosus patients. Lupus, 2021, 30, 2286-2291.	1.6	10
47	Distinct features of youth-onset primary antiphospholipid syndrome. Lupus, 2021, 30, 1888-1895.	1.6	0
48	Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases. PLoS Neglected Tropical Diseases, 2021, 15, e0010002.	3.0	5
49	2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine, 2021, 8, e000538.	2.7	97
50	Scientific legacy of COVID-19 at the FMUSP-HC academic health system: current status and implications for the future. Clinics, 2021, 76, e3630.	1.5	1
51	Use and misuse of biomarkers and the role of D-dimer and C-reactive protein in the management of COVID-19: A post-hoc analysis of a prospective cohort study. Clinics, 2021, 76, e3547.	1.5	13
52	Incidence and risk factors for moderate/severe COVID-19 in rheumatic diseases patients on hydroxychloroquine: a 24-week prospective cohort. Clinical and Experimental Rheumatology, 2021, , .	0.8	1
53	Clinical and laboratory features of African-Brazilian patients with systemic sclerosis. Clinical Rheumatology, 2020, 39, 9-17.	2.2	13
54	Anti–DNase I Antibody. Journal of Clinical Rheumatology, 2020, 26, 19-23.	0.9	2

#	Article	IF	CITATIONS
55	Associations Between Classification Criteria Items in Systemic Lupus Erythematosus. Arthritis Care and Research, 2020, 72, 1820-1826.	3.4	28
56	Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching. Clinical Rheumatology, 2020, 39, 515-521.	2.2	11
57	Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints. Kidney International Reports, 2020, 5, 1302-1305.	0.8	2
58	Childhood-onset systemic lupus erythematosus-related antiphospholipid syndrome: A multicenter study with 1519 patients. Autoimmunity Reviews, 2020, 19, 102693.	5.8	18
59	24 Refractory lupus cytopenias. , 2020, , .		0
60	Lupus nephritis-related issues during COVID-19 pandemic quarantine. Lupus, 2020, 29, 1978-1980.	1.6	5
61	Dry eye in rheumatoid arthritis patients under TNF-inhibitors: conjunctival goblet cell as an early ocular biomarker. Scientific Reports, 2020, 10, 14054.	3.3	13
62	Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis. Lupus, 2020, 29, 560-568.	1.6	18
63	Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort. Lupus, 2020, 29, 1140-1145.	1.6	1
64	Characterizing hand and wrist ultrasound pattern in primary Sjögren's syndrome: a case-control study. Clinical Rheumatology, 2020, 39, 1907-1918.	2.2	8
65	Improvement of conjunctival cytological grade and tear production in Ankylosing Spondylitis patients under TNF inhibitors: a long-term follow-up. Scientific Reports, 2020, 10, 334.	3.3	4
66	Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus. Lupus, 2020, 29, 256-262.	1.6	19
67	Abatacept induced long-term non-progressive reduction in gamma-globulins and autoantibodies: dissociation from disease activity control. Clinical Rheumatology, 2020, 39, 1747-1755.	2.2	3
68	Comparison of urinary parameters, biomarkers, and outcome of childhood systemic lupus erythematosus early onset-lupus nephritis. Advances in Rheumatology, 2020, 60, 10.	1.7	11
69	Combating physical inactivity during the COVID-19 pandemic. Nature Reviews Rheumatology, 2020, 16, 347-348.	8.0	116
70	Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: a Latin American perspective. RMD Open, 2020, 6, e001097.	3.8	26
71	Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). RMD Open, 2020, 6, e001299.	3.8	16
72	Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area. Clinics, 2020, 75, e1870.	1.5	4

#	Article	IF	CITATIONS
73	Overcoming barriers to providing comprehensive inpatient care during the COVID-19 pandemic. Clinics, 2020, 75, e2100.	1.5	13
74	Epidemiologic Surveillance in an academic hospital during the COVID-19 pandemic in Sao Paulo, Brazil: the key role of epidemiologic engagement in operational processes. Clinics, 2020, 75, e2166.	1.5	4
75	How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. Arthritis and Rheumatology, 2019, 71, 91-98.	5.6	93
76	Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort. Lupus, 2019, 28, 1101-1110.	1.6	51
77	V Brazilian consensus guidelines for detection of anti-cell autoantibodies on hep-2 cells. Advances in Rheumatology, 2019, 59, 28.	1.7	13
78	Lower genital tract infections in young female juvenile idiopathic arthritis patients. Advances in Rheumatology, 2019, 59, 50.	1.7	5
79	Panniculitis in childhood-onset systemic lupus erythematosus: a multicentric cohort study. Advances in Rheumatology, 2019, 59, 3.	1.7	4
80	Disease presentation of 1312 childhood-onset systemic lupus erythematosus: influence of ethnicity. Clinical Rheumatology, 2019, 38, 2857-2863.	2.2	20
81	Is serum uric acid a predictor of long-term renal outcome in lupus nephritis?. Clinical Rheumatology, 2019, 38, 2777-2783.	2.2	8
82	Anti-collagen type v: a marker of early systemic sclerosis?. Advances in Rheumatology, 2019, 59, 19.	1.7	4
83	Left ventricular pseudoaneurysm associated with systemic lupus erythematosus. Lupus, 2019, 28, 681-684.	1.6	2
84	Sexual function in female juvenile idiopathic arthritis patients. Advances in Rheumatology, 2019, 59, 13.	1.7	3
85	Enhanced type I interferon gene signature in primary antiphospholipid syndrome: Association with earlier disease onset and preeclampsia. Autoimmunity Reviews, 2019, 18, 393-398.	5.8	30
86	<p>Sjögren's syndrome and systemic lupus erythematosus: links and risks</p> . Open Access Rheumatology: Research and Reviews, 2019, Volume 11, 33-45.	1.6	70
87	289â€Comparison of ACR 1982/1997 and EULAR/ACR classification criteria for systemic lupus erythematosus in two multiethnic cohorts. , 2019, , .		0
88	AB0707 LTBI SCREENING IN SPONDYLOARTHRITIS PATIENTSPRIOR TO ANTI-TNF TREATMENT AND FOLLOW-LIN AN ENDEMIC AREA. , 2019, , .	JP	0
89	83â€Classification of systemic lupus erythematosus patients: the 2018 EULAR/ACR criteria vs the 1982/1997 ACR criteria. A comparative study in two multicenter multiethnic cohorts. , 2019, , .		0
90	Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. Arthritis and Rheumatology, 2019, 71, 411-419.	5.6	45

#	Article	IF	Citations
91	Late-onset biopsy-proven lupus nephritis without other associated autoimmune diseases: severity and long-term outcome. Lupus, 2019, 28, 123-128.	1.6	14
92	Response to: â€~Clinical evidence guidelines in systemic lupus erythematosus: revaluation' by Scheinberg. Annals of the Rheumatic Diseases, 2019, 78, e120-e120.	0.9	1
93	Complete urological evaluation including sperm DNA fragmentation in male systemic lupus erythematosus patients. Lupus, 2019, 28, 59-65.	1.6	9
94	Ovarian reserve in young juvenile idiopathic arthritis patients. Modern Rheumatology, 2019, 29, 447-451.	1.8	11
95	Increased visceral adipose tissue and altered adiposity distribution in premenopausal lupus patients: correlation with cardiovascular risk factors. Lupus, 2018, 27, 1001-1006.	1.6	15
96	Serum uric acid levels are associated with lupus nephritis in patients with normal renal function. Clinical Rheumatology, 2018, 37, 1223-1228.	2,2	16
97	Increased Insulin Resistance and Glucagon Levels in Mild/Inactive Systemic Lupus Erythematosus Patients Despite Normal Glucose Tolerance. Arthritis Care and Research, 2018, 70, 114-124.	3.4	25
98	Distinct clinical correlates of immune thrombocytopenic purpura at diagnosis of childhood-onset and adult SLE. Modern Rheumatology, 2018, 28, 649-653.	1.8	5
99	High rate of serious infection in juvenile idiopathic arthritis patients under biologic therapy in a real-life setting. Modern Rheumatology, 2018, 28, 264-270.	1.8	10
100	Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort. Lupus, 2018, 27, 536-544.	1.6	19
101	Large Artery Dysfunction in Primary Antiphospholipid Syndrome. Journal of Clinical Rheumatology, 2018, 24, 14-17.	0.9	1
102	Therapeutic Guidelines for Latin American Lupus Patients. Journal of Clinical Rheumatology, 2018, 24, 41-44.	0.9	7
103	Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors. Advances in Rheumatology, 2018, 58, 40.	1.7	17
104	Autoimmune hepatitis in 847 childhood-onset systemic lupus erythematosus population: a multicentric cohort study. Advances in Rheumatology, 2018, 58, 43.	1.7	7
105	AB1100â€Epidemiology and management practices for childhood-onset systemic lupus erythematosus patients: a survey in latin america. , 2018, , .		0
106	Diffuse alveolar hemorrhage in childhood-onset systemic lupus erythematosus: a severe disease flare with serious outcome. Advances in Rheumatology, 2018, 58, 39.	1.7	11
107	Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression. Lupus, 2018, 27, 2215-2219.	1.6	2
108	Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies. Advances in Rheumatology, 2018, 58, 31.	1.7	31

#	Article	IF	CITATIONS
109	Pediatric rheumatic disease patients: time to extend the age limit of adolescence?. Advances in Rheumatology, 2018, 58, 30.	1.7	6
110	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, <i>Grupo Latino Americano de Estudio del) Tj ETQq0 0 0</i>	rgBT /Ove	erlock 10 Tf 50
	Diseases, 2018, 77, 1549-1557.  Omega-3 Fatty Acid Supplementation Improves Endothelial Function in Primary Antiphospholipid		
111	Syndrome: A Small-Scale Randomized Double-Blind Placebo-Controlled Trial. Frontiers in Immunology, 2018, 9, 336.	4.8	14
112	Exercise Increases Insulin Sensitivity and Skeletal Muscle AMPK Expression in Systemic Lupus Erythematosus: A Randomized Controlled Trial. Frontiers in Immunology, 2018, 9, 906.	4.8	22
113	Characteristics of 1555 childhood-onset lupus in three groups based on distinct time intervals to disease diagnosis: a Brazilian multicenter study. Lupus, 2018, 27, 1712-1717.	1.6	18
114	Non-steroidal anti-inflammatory drug induces luteinized unruptured follicle syndrome in young female juvenile idiopathic arthritis patients. Clinical Rheumatology, 2018, 37, 2869-2873.	2.2	14
115	Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis. Rheumatology, 2018, 57, 1721-1725.	1.9	9
116	Budd-Chiari syndrome, large regenerative nodules and hepatocellular carcinoma in antiphospholipid syndrome associated with juvenile systemic lupus erythematosus. Modern Rheumatology Case Reports, 2018, 2, 20-24.	0.7	0
117	Epidemiology and management practices for childhood-onset systemic lupus erythematosus patients: a survey in Latin America. Clinical Rheumatology, 2018, 37, 3299-3307.	2.2	19
118	Symptomatic polyautoimmunity at diagnosis of 1463 childhood-onset lupus: A Brazilian multicenter study. Autoimmunity Reviews, 2018, 17, 836-839.	5.8	18
119	Anti-alpha-enolase antibodies in Behçet's disease: a marker of mucocutaneous and articular disease activity?. Clinical and Experimental Rheumatology, 2018, 36, 28-32.	0.8	2
120	Early discoid lupus erythematosus protects against renal disease in patients with systemic lupus erythematosus: longitudinal data from a large Latin American cohort. Lupus, 2017, 26, 73-83.	1.6	8
121	Analysis of sexual function of patients with dermatomyositis and polymyositis through self-administered questionnaires: a cross-sectional study. Revista Brasileira De Reumatologia, 2017, 57, 134-140.	0.7	3
122	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561.	0.9	268
123	Uveitis in childhood-onset systemic lupus erythematosus patients: a multicenter survey. Clinical Rheumatology, 2017, 36, 547-553.	2.2	13
124	Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. Seminars in Arthritis and Rheumatism, 2017, 47, 199-203.	3.4	11
125	Outcomes of 847 childhood-onset systemic lupus erythematosus patients in three age groups. Lupus, 2017, 26, 996-1001.	1.6	42
126	Electrophysiological dysfunction induced by anti-ribosomal P protein antibodies injection into the lateral ventricle of the rat brain. Lupus, 2017, 26, 463-469.	1.6	12

#	Article	IF	Citations
127	Anti-ribosomal P antibody: a multicenter study in childhood-onset systemic lupus erythematosus patients. Lupus, 2017, 26, 484-489.	1.6	12
128	Ribosomal P antibody: 30 years on the road. Lupus, 2017, 26, 453-462.	1.6	19
129	Physical inactivity and sedentary behavior: Overlooked risk factors in autoimmune rheumatic diseases?. Autoimmunity Reviews, 2017, 16, 667-674.	5.8	64
130	Longitudinal Extensive Transverse Myelitis and Central Diabetes Insipidus. Journal of Clinical Rheumatology, 2017, 23, 122-124.	0.9	0
131	Physical activity for paediatric rheumatic diseases: standing up against old paradigms. Nature Reviews Rheumatology, 2017, 13, 368-379.	8.0	48
132	Pleuropulmonary involvement in patients with systemic lupus erythematosus from a Latin American inception cohort (GLADEL). Lupus, 2017, 26, 1368-1377.	1.6	22
133	Anti-RO/SSA and anti-La/SSB antibodies: Association with mild lupus manifestations in 645 childhood-onset systemic lupus erythematosus. Autoimmunity Reviews, 2017, 16, 132-135.	5.8	36
134	Latent tuberculosis infection screening in juvenile idiopathic arthritis patients preceding anti-TNF therapy in a tuberculosis high-risk country. Revista Brasileira De Reumatologia, 2017, 57, 392-396.	0.7	7
135	Initial digital vasculitis in a large multicenter cohort of childhood-onset systemic lupus erythematosus. Revista Brasileira De Reumatologia, 2017, 57, 583-589.	0.7	5
136	Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). Annals of the Rheumatic Diseases, 2017, 76, 2071-2074.	0.9	89
137	Vasculite digital inicial em uma grande coorte multicêntrica de pacientes com lúpus eritematoso sistêmico de inÃcio na infância. Revista Brasileira De Reumatologia, 2017, 57, 583-589.	0.8	4
138	Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?. Lupus Science and Medicine, 2017, 4, e000213.	2.7	82
139	$192 \hat{a} \in$ Protective effect of antimalarials on the risk of damage accrual in systemic lupus erythematosus. , 2017, , .		0
140	OP0061â€Diffuse alveolar hemorrhage: a multicenter study in 847 childhood-onset systemic lupus erythematosus patients. , 2017, , .		0
141	Subclinical Pulmonary Hypertension in Childhood Systemic Lupus Erythematosus Associated with Minor Disease Manifestations. Pediatric Cardiology, 2017, 38, 234-239.	1.3	11
142	Autoimmune hemolytic anemia in systemic lupus erythematosus at diagnosis: differences between pediatric and adult patients. Lupus, 2017, 26, 426-430.	1.6	30
143	Análise da função sexual de pacientes com dermatomiosite e polimiosite através de questionários autoaplicados: um estudo transversal. Revista Brasileira De Reumatologia, 2017, 57, 134-140.	0.8	4
144	Rastreamento da infecção latente por tuberculose em pacientes com artrite idiopática juvenil previamente à terapia antiâ€TNF em um paÃs de alto risco para tuberculose. Revista Brasileira De Reumatologia, 2017, 57, 392-396.	0.8	7

#	Article	IF	CITATIONS
145	128â€Outcomes of 847 childhood-onset systemic lupus erythematousus patients in three age groups. , 2017, , .		O
146	129â€Panniculitis in childhood-onset systemic lupus erythematosus: a multicentric cohort study. , 2017, , .		0
147	Male fertility potential alteration in rheumatic diseases: a systematic review. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 11-21.	1.5	46
148	Anti-inflammatory effects of intravenous methotrexate associated with lipid nanoemulsions on antigen-induced arthritis. Clinics, 2016, 71, 54-58.	1.5	10
149	Pancreatitis Subtypes Survey in 852 Childhoodâ€Onset Systemic Lupus Erythematosus Patients. Journal of Pediatric Gastroenterology and Nutrition, 2016, 62, 328-334.	1.8	22
150	Evans Syndrome at Childhoodâ€Onset Systemic Lupus Erythematosus Diagnosis: A Large Multicenter Study. Pediatric Blood and Cancer, 2016, 63, 1238-1243.	1.5	16
151	Features of 847 Childhoodâ€Onset Systemic Lupus Erythematosus Patients in Three Age Groups at Diagnosis: A Brazilian Multicenter Study. Arthritis Care and Research, 2016, 68, 1736-1741.	3.4	52
152	SAT0253â€Evans Syndrome at Childhood-Onset Systemic Lupus Erythematosus Diagnosis: A Large Multicenter Study. Annals of the Rheumatic Diseases, 2016, 75, 760.2-760.	0.9	0
153	First-case tardiness reduction in a tertiary academic medical center operating room: A lean six sigma perspective. Perioperative Care and Operating Room Management, 2016, 5, 7-12.	0.3	5
154	Estudo prospectivo de fatores prognósticos em lombalgia crônica tratados com fisioterapia: papel do medoâ€evitação e dor extraespinal. Revista Brasileira De Reumatologia, 2016, 56, 384-390.	0.8	8
155	Ozone decreases sperm quality in systemic lupus erythematosus patients. Revista Brasileira De Reumatologia, 2016, 56, 212-219.	0.7	4
156	A prospective study predicting the outcome of chronic low back pain and physical therapy: the role of fear-avoidance beliefs and extraspinal pain. Revista Brasileira De Reumatologia, 2016, 56, 384-390.	0.7	4
157	Hepatitis C virus antibodies in high risk juvenile onset systemic lupus erythematosus. Revista Brasileira De Reumatologia, 2016, 56, 235-239.	0.7	2
158	Low vitamin D serum levels in diffuse systemic sclerosis: a correlation with worst quality of life and severe capillaroscopic findings. Revista Brasileira De Reumatologia, 2016, 56, 337-344.	0.7	23
159	Cortical bone density and thickness alterations by high-resolution peripheral quantitative computed tomography: association with vertebral fractures in primary Sjögren's syndrome. Rheumatology, 2016, 55, 2200-2211.	1.9	17
160	Vitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial. Arthritis Care and Research, 2016, 68, 91-98.	3.4	117
161	Characterization of chronic arthritis in a multicenter study of 852 childhood-onset systemic lupus erythematosus patients. Rheumatology International, 2016, 36, 1641-1648.	3.0	11
162	Systemic and localized infection by Candida species in patients with rheumatic diseases receiving anti-TNF therapy. Revista Brasileira De Reumatologia, 2016, 56, 478-482.	0.7	6

#	Article	IF	CITATIONS
163	IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients. Arthritis Research and Therapy, 2016, 18, 52.	3.5	35
164	Bone impairment assessed by HR-pQCT in juvenile-onset systemic lupus erythematosus. Osteoporosis International, 2016, 27, 1839-1848.	3.1	26
165	Reduced Aerobic Capacity and Quality of Life in Physically Inactive Patients With Systemic Lupus Erythematosus With Mild or Inactive Disease. Arthritis Care and Research, 2016, 68, 1780-1786.	3.4	35
166	Juvenile idiopathic arthritis activity and function ability: deleterious effects in periodontal disease?. Clinical Rheumatology, 2016, 35, 81-91.	2.2	21
167	Chronic arthritis in systemic lupus erythematosus: distinct features in 336 paediatric and 1830 adult patients. Clinical Rheumatology, 2016, 35, 227-231.	2.2	21
168	Macrophage activation syndrome: A severe and frequent manifestation of acute pancreatitis in 362 childhood-onset compared to 1830 adult-onset systemic lupus erythematosus patients. Seminars in Arthritis and Rheumatism, 2016, 45, 706-710.	3.4	32
169	Primary antiphospholipid syndrome: absence of premature atherosclerosis in patients without traditional coronary artery disease risk factors. Lupus, 2016, 25, 472-478.	1.6	19
170	Herpes zoster infection in childhood-onset systemic lupus erythematosus patients: a large multicenter study. Lupus, 2016, 25, 754-759.	1.6	25
171	Metabolic syndrome in Sjögren's syndrome patients: a relevant concern for clinical monitoring. Clinical Rheumatology, 2016, 35, 639-647.	2.2	29
172	Subclinical left ventricular dysfunction in childhood-onset systemic lupus erythematosus: a two-dimensional speckle-tracking echocardiographic study. Scandinavian Journal of Rheumatology, 2016, 45, 202-209.	1.1	18
173	Using the Manchester triage system for refusing nonurgent patients in the emergency department: A 30-day outcome study. Journal of Emergency Management, 2016, 14, 365-369.	0.3	8
174	Effects of acute aerobic exercise on leukocyte inflammatory gene expression in systemic lupus erythematosus. Exercise Immunology Review, 2016, 22, 64-81.	0.4	9
175	Higher Prevalence and Distinct Features of Herpes Zoster Infection in Children than Adults with Systemic Lupus Erythematosus. Pediatric Infectious Disease Journal, 2015, 34, 905-907.	2.0	14
176	Impact of Therapy on Metabolic Syndrome in Young Adult Premenopausal Female Lupus Patients: Beneficial Effect of Antimalarials. Arthritis Care and Research, 2015, 67, 1255-1262.	3.4	19
177	THU0517â€Invasive Fungal Infections Survey in 852 Childhood-Onset Systemic Lupus Erythematosus: A Multicenter Cohort. Annals of the Rheumatic Diseases, 2015, 74, 387.2-387.	0.9	0
178	Periodontitis Response to Anti-TNF Therapy in Ankylosing Spondylitis. Journal of Clinical Rheumatology, 2015, 21, 341-345.	0.9	25
179	Subclinical right ventricle systolic dysfunction in childhood-onset systemic lupus erythematosus: insights from two-dimensional speckle-tracking echocardiography. Lupus, 2015, 24, 613-620.	1.6	38
180	Clark CA, Laskin CA. Ovarian reserve in antiphospholipid syndrome: the jury is still out. <i>Lupus</i> 2015; 24: 773. Lupus, 2015, 24, 1007-1007.	1.6	0

#	Article	IF	Citations
181	Chronic Spontaneous Urticaria: A Survey of 852 Cases of Childhood-Onset Systemic Lupus Erythematosus. International Archives of Allergy and Immunology, 2015, 167, 186-192.	2.1	25
182	Plasma kinetics of an LDL-like non-protein nanoemulsion and transfer of lipids to high-density lipoprotein (HDL) in patients with rheumatoid arthritis. Journal of Clinical Lipidology, 2015, 9, 72-80.	1.5	6
183	Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy. Vaccine, 2015, 33, 604-609.	3.8	25
184	ABO blood group in primary antiphospholipid syndrome: influence in the site of thrombosis?. Journal of Thrombosis and Thrombolysis, 2015, 40, 374-378.	2.1	5
185	Lower P1NP serum levels: a predictive marker of bone loss after 1Âyear follow-up in premenopausal systemic lupus erythematosus patients. Osteoporosis International, 2015, 26, 459-467.	3.1	19
186	RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus. Osteoporosis International, 2015, 26, 1563-1571.	3.1	41
187	The effects of exercise on lipid profile in systemic lupus erythematosus and healthy individuals: a randomized trial. Rheumatology International, 2015, 35, 61-69.	3.0	22
188	Circulating Follicular Helper–Like T Cells in Systemic Lupus Erythematosus: Association With Disease Activity. Arthritis and Rheumatology, 2015, 67, 988-999.	5.6	264
189	Lupus in Latin-American patients: lessons from the GLADEL cohort. Lupus, 2015, 24, 536-545.	1.6	54
190	Increased corticotropin-releasing hormone (CRH) expression in cutaneous lupus lesions. Lupus, 2015, 24, 854-861.	1.6	3
191	Late-onset systemic lupus erythematosus in Latin Americans: a distinct subgroup?. Lupus, 2015, 24, 788-795.	1.6	39
192	The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Annals of the Rheumatic Diseases, 2015, 74, 1019-1023.	0.9	100
193	Carpal tunnel syndrome and prediabetes: Is there a true association?. Clinical Neurology and Neurosurgery, 2015, 137, 57-61.	1.4	4
194	Human papillomavirus and chlamydia trachomatis infections in rheumatoid arthritis under anti-TNF therapy: an observational study. Rheumatology International, 2015, 35, 459-463.	3.0	11
195	Antiâ€ribosomal P protein antibody and prognosis in autoimmune hepatitis. Liver International, 2015, 35, 676-676.	3.9	3
196	Reduced ovarian reserve in patients with adult polymyositis. Clinical Rheumatology, 2015, 34, 1795-1799.	2.2	16
197	Maternal and Neonatal Outcomes in 89 Patients with Takayasu Arteritis (TA): Comparison Before and After the TA Diagnosis. Journal of Rheumatology, 2015, 42, 1861-1864.	2.0	45
198	A Multicenter Study of Invasive Fungal Infections in Patients with Childhood-onset Systemic Lupus Erythematosus. Journal of Rheumatology, 2015, 42, 2296-2303.	2.0	39

#	Article	IF	Citations
199	Diminished ovarian reserve in Behçet's disease patients. Clinical Rheumatology, 2015, 34, 179-183.	2.2	30
200	Temporal Dissociation between Disease Activity Reduction and Improvements in Fatigue and Physical Function After Infliximab in Rheumatoid Arthritis. Rheumatology (Sunnyvale, Calif), 2015, 05, .	0.3	0
201	Reduction of ovarian reserve in adult patients with dermatomyositis. Clinical and Experimental Rheumatology, 2015, 33, 44-9.	0.8	15
202	Inflammatory cytokine kinetics to single bouts of acute moderate and intense aerobic exercise in women with active and inactive systemic lupus erythematosus. Exercise Immunology Review, 2015, 21, 174-85.	0.4	19
203	AB0185 Increased Corticotropin-Releasing Hormone (CRH) Expression in Cutaneous Lupus Lesions. Annals of the Rheumatic Diseases, 2014, 73, 864.1-864.	0.9	0
204	FRIO493â€Clinical and Serological Comparative Analysis of Systemic Sclerosis with or without Overlap Syndromes in A Large Brazilian Cohort. Annals of the Rheumatic Diseases, 2014, 73, 565.3-565.	0.9	0
205	AB0637â€Systemic Sclerosis-Related Auto-Antibodies Are Markers of New Clinical Associations in A Cohort of 328 Brazilian Patients. Annals of the Rheumatic Diseases, 2014, 73, 1016.2-1016.	0.9	0
206	Ovarian reserve in women with primary antiphospholipid syndrome. Lupus, 2014, 23, 862-867.	1.6	32
207	The clinical utility of anti-ribosomal P autoantibodies in systemic lupus erythematosus. Expert Review of Clinical Immunology, 2014, 10, 1493-1503.	3.0	25
208	Ovarian reserve in adult patients with childhood-onset lupus: a possible deleterious effect of methotrexate?. Scandinavian Journal of Rheumatology, 2014, 43, 503-511.	1.1	32
209	Determinants of Arterial Stiffness in Female Patients with Takayasu Arteritis. Journal of Rheumatology, 2014, 41, 1374-1378.	2.0	15
210	LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area. International Journal of Tuberculosis and Lung Disease, 2014, 18, 905-911.	1.2	34
211	The antiâ€ribosomal P antibodies and prognosis in autoimmune hepatitis. Liver International, 2014, 34, 324-324.	3.9	2
212	Exercise training can attenuate the inflammatory milieu in women with systemic lupus erythematosus. Journal of Applied Physiology, 2014, 117, 639-647.	2.5	44
213	Evidence for cardiac safety and antiarrhythmic potential of chloroquine in systemic lupus erythematosus. Europace, 2014, 16, 887-892.	1.7	44
214	Update on infections and vaccinations in systemic lupus erythematosus and Sjögren's syndrome. Current Opinion in Rheumatology, 2014, 26, 528-537.	4.3	48
215	Pandemic influenza immunization in primary antiphospholipid syndrome (PAPS): a trigger to thrombosis and autoantibody production?. Lupus, 2014, 23, 1412-1416.	1.6	9
216	Reduced Ovarian Reserve in Patients with Takayasu Arteritis. Journal of Rheumatology, 2014, 41, 2055-2059.	2.0	31

#	Article	IF	CITATIONS
217	IV Brazilian Guidelines for autoantibodies on HEp-2 cells. Revista Brasileira De Reumatologia, 2014, 54, 44-50.	0.7	9
218	Prevalence of sarcopenia and associated risk factors by two diagnostic criteria in community-dwelling older men: the São Paulo Ageing & Dealth Study (SPAH). Osteoporosis International, 2014, 25, 589-596.	3.1	47
219	Periodontitis treatment improves systemic lupus erythematosus response to immunosuppressive therapy. Clinical Rheumatology, 2014, 33, 505-509.	2.2	57
220	Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factors-data from a multi-ethnic Latin American cohort. Rheumatology, 2014, 53, 1431-1438.	1.9	33
221	Distinct antibody profile: a clue to primary antiphospholipid syndrome evolving into systemic lupus erythematosus?. Clinical Rheumatology, 2014, 33, 349-353.	2.2	13
222	Autoimmune primary ovarian insufficiency. Autoimmunity Reviews, 2014, 13, 427-430.	5.8	131
223	Cross-cultural adaptation and validation of the Brazilian version of the Scleroderma Health Assessment Questionnaire (SHAQ). Clinical Rheumatology, 2014, 33, 699-706.	2.2	13
224	Periodontal disease in pediatric rheumatic diseases. Revista Brasileira De Reumatologia, 2014, 54, 311-317.	0.7	2
225	Podocyte injury in pure membranous and proliferative lupus nephritis: distinct underlying mechanisms of proteinuria?. Lupus, 2014, 23, 255-262.	1.6	40
226	Acute physical exercise is safe in patients with primary antiphospholipid syndrome with exclusive venous thrombosis and under oral anticoagulation with warfarin. Rheumatology International, 2014, 34, 1737-1741.	3.0	4
227	Diagnosis and classification of autoimmune orchitis. Autoimmunity Reviews, 2014, 13, 431-434.	5.8	60
228	THU0056â€Acute Aerobic Exercise Induces Increases on Plasma Levels of α-Melanocyte Stimulating Hormone in Patients with Active Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2014, 73, 195.2-195.	0.9	0
229	Increased arterial stiffness assessed by pulse wave velocity in Behçet's disease and its association with the lipid profile. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 454-459.	2.4	18
230	Exercise training in childhood-onset systemic lupus erythematosus: a controlled randomized trial. Arthritis Research and Therapy, 2013, 15, R46.	3.5	46
231	Vaccinations in juvenile chronic inflammatory diseases: an update. Nature Reviews Rheumatology, 2013, 9, 532-543.	8.0	40
232	NT-proBNP levels may be influenced by inflammation in active ankylosing spondylitis receiving TNF blockers: a pilot study. Clinical Rheumatology, 2013, 32, 879-883.	2.2	15
233	Testicular Sertoli cell function in ankylosing spondylitis. Clinical Rheumatology, 2013, 32, 1075-1079.	2.2	24
234	EBV reactivation serological profile in primary Sjögren's syndrome: an underlying trigger of active articular involvement?. Rheumatology International, 2013, 33, 1149-1157.	3.0	31

#	Article	IF	Citations
235	Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: Data from a Latin American cohort. Lupus, 2013, 22, 899-907.	1.6	42
236	Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis. Scandinavian Journal of Rheumatology, 2013, 42, 34-40.	1.1	28
237	Impaired aerobic exercise capacity and cardiac autonomic control in primary antiphospholipid syndrome. Lupus, 2013, 22, 928-931.	1.6	9
238	Clinical and immunological features of 888 Brazilian systemic lupus patients from a monocentric cohort: comparison with other populations. Lupus, 2013, 22, 744-749.	1.6	30
239	Discriminating sarcopenia in community-dwelling older women with high frequency of overweight/obesity: the São Paulo Ageing & Health Study (SPAH). Osteoporosis International, 2013, 24, 595-603.	3.1	62
240	Penile alterations with severe sperm abnormalities in antiphospholipid syndrome associated with systemic lupus erythematosus. Clinical Rheumatology, 2013, 32, 109-113.	2.2	23
241	Short and long-term effects of pandemic unadjuvanted influenza A(H1N1)pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sjögren's syndrome. Vaccine, 2013, 31, 1793-1798.	3.8	27
242	Antiâ€ribosomal <scp>P</scp> protein: a novel antibody in autoimmune hepatitis. Liver International, 2013, 33, 909-913.	3.9	40
243	Creatine Supplementation in Fibromyalgia: A Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial. Arthritis Care and Research, 2013, 65, 1449-1459.	3.4	47
244	Serum phosphate and hip bone mineral density as additional factors for high vascular calcification scores in a community-dwelling: The São Paulo Ageing & Health Study (SPAH). Bone, 2013, 52, 354-359.	2.9	31
245	Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients. Lupus, 2013, 22, 1394-1398.	1.6	17
246	High Prevalence of Metabolic Syndrome in Takayasu Arteritis: Increased Cardiovascular Risk and Lower Adiponectin Serum Levels. Journal of Rheumatology, 2013, 40, 1897-1904.	2.0	32
247	Vertebral Fracture Assessment by Dual Xâ€Ray Absorptiometry: A Valid Tool to Detect Vertebral Fractures in Communityâ€Dwelling Older Adults in a Populationâ€Based Survey. Arthritis Care and Research, 2013, 65, 809-815.	3.4	40
248	High Disease Activity: An Independent Factor for Reduced Immunogenicity of the Pandemic Influenza A Vaccine in Patients With Juvenile Systemic Lupus Erythematosus. Arthritis Care and Research, 2013, 65, 1121-1127.	3.4	59
249	Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care and Research, 2013, 65, 476-480.	3.4	95
250	SAT0146â€BehÇEt´S Disease Activity: An Important Factor for Immunogenecity of Unadjuvanted Influenza A/H1N1 Vaccine. Annals of the Rheumatic Diseases, 2013, 72, A631.2-A631.	0.9	0
251	Intra-articular methotrexate associated to lipid nanoemulsions: anti-inflammatory effect upon antigen-induced arthritis. International Journal of Nanomedicine, 2013, 8, 443.	6.7	20
252	Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy. Clinics, 2013, 68, 129-133.	1.5	14

#	Article	IF	CITATIONS
253	AB0519â€Auto-antibody titers for monitoring rituximab therapy in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 71, 667.14-667.	0.9	4
254	Heparin Increases HLA-G Levels in Primary Antiphospholipid Syndrome. Clinical and Developmental Immunology, 2012, 2012, 1-5.	3.3	4
255	Juvenile onset systemic lupus erythematosus: a possible role for vitamin D in disease status and bone health. Lupus, 2012, 21, 1335-1342.	1.6	45
256	Alveolar hemorrhage: distinct features of juvenile and adult onset systemic lupus erythematosus. Lupus, 2012, 21, 872-877.	1.6	50
257	TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology, 2012, 51, 2091-2098.	1.9	56
258	Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?. Rheumatology, 2012, 51, 1061-1069.	1.9	57
259	Glucocorticoid: Major Factor for Reduced Immunogenicity of 2009 Influenza A (H1N1) Vaccine in Patients with Juvenile Autoimmune Rheumatic Disease. Journal of Rheumatology, 2012, 39, 167-173.	2.0	70
260	Persistent Periodontal Disease Hampers Anti–Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2012, 18, 1.	0.9	59
261	Gonadal function in male patients with ankylosing spondylitis. Scandinavian Journal of Rheumatology, 2012, 41, 476-481.	1.1	28
262	Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren's syndrome. Clinical Rheumatology, 2012, 31, 1331-1338.	2.2	44
263	Exercise as a therapeutic tool to counteract inflammation and clinical symptoms in autoimmune rheumatic diseases. Autoimmunity Reviews, 2012, 12, 218-224.	5.8	85
264	Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: Immunogenicity independent of therapy and no harmful effect in disease. Vaccine, 2012, 31, 202-206.	3.8	17
265	Primary antiphospholipid syndrome: morphofunctional penile abnormalities with normal sperm analysis. Lupus, 2012, 21, 251-256.	1.6	19
266	Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome. Arthritis Care and Research, 2012, 64, 1576-1583.	3.4	24
267	Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?. Arthritis Research and Therapy, 2012, 14, R216.	3.5	58
268	Osteoporotic hip fractures in non-elderly patients: relevance of associated co-morbidities. Rheumatology International, 2012, 32, 3149-3153.	3.0	14
269	Dieta e aspectos nutricionais no lúpus eritematoso sistúmico. Revista Brasileira De Reumatologia, 2012, 52, 395-408.	0.8	28
270	Using exercise training to counterbalance chronotropic incompetence and delayed heart rate recovery in systemic lupus erythematosus: A randomized trial. Arthritis Care and Research, 2012, 64, 1159-1166.	3.4	34

#	Article	IF	Citations
271	Cutting-Edge Issues in Autoimmune Orchitis. Clinical Reviews in Allergy and Immunology, 2012, 42, 256-263.	6.5	33
272	Anti-TNF therapy for polymyalgia rheumatica: report of 99 cases and review of the literature. Clinical Rheumatology, 2012, 31, 575-579.	2.2	13
273	Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy. Clinical and Experimental Rheumatology, 2012, 30, 445-9.	0.8	27
274	Influenza A H1N1/2009 vaccine in juvenile dermatomyositis: reduced immunogenicity in patients under immunosuppressive therapy. Clinical and Experimental Rheumatology, 2012, 30, 583-8.	0.8	17
275	Hearing loss in diffuse cutaneous systemic scleroderma. Scandinavian Journal of Rheumatology, 2011, 40, 467-471.	1.1	13
276	Erratic control of breathing during exercise in patients with systemic lupus erythematosus: a pilot-study. Lupus, 2011, 20, 1535-1540.	1.6	11
277	Effect of creatine supplementation on measured glomerular filtration rate in postmenopausal women. Applied Physiology, Nutrition and Metabolism, 2011, 36, 419-422.	1.9	24
278	Cardiac autonomic impairment and chronotropic incompetence in fibromyalgia. Arthritis Research and Therapy, 2011, 13, R190.	3.5	44
279	No deleterious effect of low dose methotrexate on titanium implant osseointegration in a rabbit model. Clinics, 2011, 66, 1055-1059.	1.5	5
280	Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?. Clinics, 2011, 66, 1171-1175.	1.5	14
281	Decreased high-density lipoprotein cholesterol levels in polyarticular juvenile idiopathic arthritis. Clinics, 2011, 66, 1549-1552.	1.5	20
282	A novel 60kDa reactivity in cyclic neutropenia: High titer cytoplasmic ANCA immunostaining pattern and negative anti-proteinase-3 antibody. Joint Bone Spine, 2011, 78, 319-320.	1.6	4
283	Antibodies to ribosomal P proteins in lupus nephritis: A surrogate marker for a better renal survival?. Autoimmunity Reviews, 2011, 10, 126-130.	5.8	23
284	Penile anthropometry in systemic lupus erythematosus patients. Lupus, 2011, 20, 512-518.	1.6	27
285	Creatine supplementation does not impair kidney function in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial. European Journal of Applied Physiology, 2011, 111, 749-756.	2.5	51
286	Cutaneous vasculitis in systemic lupus erythematosus: association with anti-ribosomal P protein antibody and Raynaud phenomenon. Clinical Rheumatology, 2011, 30, 173-177.	2.2	14
287	A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma. Clinical Rheumatology, 2011, 30, 223-229.	2.2	33
288	ls anti-TNF switching in refractory Still's disease safe and effective?. Clinical Rheumatology, 2011, 30, 1129-1134.	2.2	17

#	Article	IF	Citations
289	Late response to anti-TNF-î± therapy in refractory mucocutaneous lesions of Behçet's disease. Rheumatology International, 2011, 31, 1097-1099.	3.0	16
290	Hormone profile in juvenile systemic lupus erythematosus with previous or current amenorrhea. Rheumatology International, 2011, 31, 1037-1043.	3.0	28
291	Low bone mass in juvenile onset sclerosis systemic: the possible role for 25-hydroxyvitamin D insufficiency. Rheumatology International, 2011, 31, 1075-1080.	3.0	20
292	Fatal rhabdomyolysis in systemic lupus erythematosus. Rheumatology International, 2011, 31, 1243-1245.	3.0	13
293	Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Annals of the Rheumatic Diseases, 2011, 70, 1068-1073.	0.9	87
294	Beneficial Effect of Creatine Supplementation in Knee Osteoarthritis. Medicine and Science in Sports and Exercise, 2011, 43, 1538-1543.	0.4	46
295	Abnormal chronotropic reserve and heart rate recovery in patients with SLE: a case–control study. Lupus, 2011, 20, 717-720.	1.6	20
296	Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients. Clinical and Developmental Immunology, 2011, 2011, 1-5.	3.3	25
297	PPARÎ <sup>3</sup> expression is increased in systemic lupus erythematosus patients and represses CD40/CD40L signaling pathway. Lupus, 2011, 20, 575-587.	1.6	27
298	Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Annals of the Rheumatic Diseases, 2011, 70, 2144-2147.	0.9	76
299	Creatine in Type 2 Diabetes. Medicine and Science in Sports and Exercise, 2011, 43, 770-778.	0.4	79
300	Hypoparathyroidism mimicking ankylosing spondylitis and myopathy: a case report. Clinics, 2011, 66, 1287-1290.	1.5	10
301	Clues for Previously Undiagnosed Connective Tissue Disease in Patients With Trigeminal Neuralgia. Journal of Clinical Rheumatology, 2010, 16, 205-208.	0.9	14
302	Incidence, Risk Factors, and Outcome of Herpes Zoster in Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2010, 16, 119-122.	0.9	67
303	Resistance Training with Vascular Occlusion in Inclusion Body Myositis. Medicine and Science in Sports and Exercise, 2010, 42, 250-254.	0.4	88
304	A single dose of zoledronic acid reverses the deleterious effects of glucocorticoids on titanium implant osseointegration. Osteoporosis International, 2010, 21, 1723-1729.	3.1	27
305	Male gender results in more severe lupus nephritis. Rheumatology International, 2010, 30, 1311-1315.	3.0	53
306	Immunogenicity of Anti-TNF- $\hat{l}_{\pm}$ Agents in Autoimmune Diseases. Clinical Reviews in Allergy and Immunology, 2010, 38, 82-89.	6.5	156

#	Article	IF	CITATIONS
307	Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis. Biologicals, 2010, 38, 567-569.	1.4	27
308	Maintenance of fertility in patients with rheumatic diseases needing antiinflammatory and immunosuppressive drugs. Arthritis Care and Research, 2010, 62, 1682-1690.	3.4	66
309	Antimalarial treatment may have a timeâ€dependent effect on lupus survival: Data from a multinational Latin American inception cohort. Arthritis and Rheumatism, 2010, 62, 855-862.	6.7	177
310	Pesquisa de autoanticorpos em pacientes com artrite psoriásica sob terapia anti-TNFα. Revista Brasileira De Reumatologia, 2010, 50, 225-234.	0.8	16
311	Avaliação clÃnico-laboratorial de pacientes com sÃndrome antifosfolÃpide primária segundo a frequência de anticorpos antinucleares (FAN Hep-2). Revista Brasileira De Reumatologia, 2010, 50, 262-272.	0.8	7
312	Detecção precoce da disfunção diastólica global e regional do ventrÃculo esquerdo no lúpus eritematoso sistêmico: o papel da ecocardiografia. Revista Brasileira De Reumatologia, 2010, 50, 16-30.	0.8	16
313	Premature coronary artery calcification is associated with disease duration and bone mineral density in young female systemic lupus erythematosus patients. Lupus, 2010, 19, 27-33.	1.6	27
314	Peripheral neuropathy in patients with primary antiphospholipid (Hughes') syndrome. Lupus, 2010, 19, 583-590.	1.6	19
315	Gingival capillary changes and oral motor weakness in juvenile dermatomyositis. Rheumatology, 2010, 49, 1962-1970.	1.9	18
316	A 12-month randomized controlled trial of balance training in elderly women with osteoporosis: Improvement of quality of life. Maturitas, 2010, 66, 206-211.	2.4	63
317	Interleukin-1 receptor antagonist gene (IL1RN) polymorphism possibly associated to severity of rheumatic carditis in a Brazilian cohort. Cytokine, 2010, 49, 109-113.	3.2	28
318	Review on anti-lipoprotein lipase antibodies. Clinica Chimica Acta, 2010, 411, 1603-1605.	1.1	13
319	Lupus pleuritis: a relevant risk factor for pulmonary tuberculosis. Lupus, 2010, 19, 1585-1590.	1.6	14
320	Juvenile-onset Takayasu arteritis: peculiar vascular involvement and more refractory disease. Scandinavian Journal of Rheumatology, 2010, 39, 506-510.	1.1	38
321	Eventos arrÃŧmicos no lúpus eritematoso sistêmico. Revista Brasileira De Reumatologia, 2010, 50, 81-89.	0.8	31
322	Complicações Imediatas de 3.555 aplicações de agentes anti-TNFα. Revista Brasileira De Reumatologia, 2010, 50, 165-170.	0.8	12
323	Gonad evaluation in male dermatomyositis. A pilot study. Clinical and Experimental Rheumatology, 2010, 28, 441-2.	0.8	10
324	Menstrual and hormonal alterations in juvenile dermatomyositis. Clinical and Experimental Rheumatology, 2010, 28, 571-5.	0.8	19

#	Article	IF	CITATIONS
325	3º Consenso Brasileiro para pesquisa de autoanticorpos em células HEp-2 (FAN): recomendações para padronização do ensaio de pesquisa de autoanticorpos em células HEp-2, controle de qualidade e associações clÃnicas. Revista Brasileira De Reumatologia, 2009, 49, 89-98.	0.8	26
326	Guidelines on Management of Human Infection with the Novel Virus Influenza A (H1N1) – A Report from the Hospital das ClÃnicas of the University of São Paulo. Clinics, 2009, 64, 1015-1024.	1.5	11
327	Estudo longitudinal do anticorpo antilipoproteÃna lipase e sua relação com atividade de doença nos indivÃduos com lúpus eritematoso sistúmico sem anticorpos anti-dsDNA. Revista Brasileira De Reumatologia, 2009, 49, 39-47.	0.8	1
328	Sa $\tilde{A}^{\circ}$ de reprodutiva em homens com l $\tilde{A}^{\circ}$ pus eritematoso sist $\tilde{A}^{\circ}$ mico. Revista Brasileira De Reumatologia, 2009, 49, .	0.8	4
329	Frequência de anticorpos aos agentes etiológicos da sÃndrome da imunodeficiência adquirida, sÃfilis, hepatites virais B e C e doença de Chagas em pacientes reumatológicos em tratamento com antifator de necrose tumoral (Tumor Necrosis Factor - TNF). Revista Brasileira De Reumatologia, 2009, 49, .	0.8	1
330	Aspectos da saúde reprodutiva em homens com miopatia inflamatória idiopática: um estudo multicêntrico. Revista Brasileira De Reumatologia, 2009, 49, 677-689.	0.8	3
331	Epidemiology of human infection with the novel virus influenza A (H1H1) in the Hospital das ClÃnicas, São Paulo, Brazil - june-september 2009. Clinics, 2009, 64, 1025-1030.	1.5	29
332	Ausência de anticorpos antilipoproteÃna lipase na doença de Behçet. Revista Brasileira De Reumatologia, 2009, 49, 670-676.	0.8	1
333	Função sexual e saúde reprodutiva em mulheres adolescentes com lúpus eritematoso sistêmico juvenil. Revista Brasileira De Reumatologia, 2009, 49, 690-702.	0.8	9
334	Menstrual and hormonal alterations in juvenile systemic lupus erythematosus. Lupus, 2009, 18, 38-43.	1.6	67
335	Centrilobular Fibrosis: An Underrecognized Pattern in Systemic Sclerosis. Respiration, 2009, 77, 389-397.	2.6	54
336	Ovarian necrotizing vasculitis in a patient with lupus. Lupus, 2009, 18, 1313-1315.	1.6	7
337	Lack of Antilipoprotein Lipase Antibodies in Takayasu's Arteritis. Clinical and Developmental Immunology, 2009, 2009, 1-4.	3.3	3
338	Validation of the Spanish, Portuguese and French versions of the Lupus Damage Index questionnaire: data from North and South America, Spain and Portugal. Lupus, 2009, 18, 1033-1052.	1.6	20
339	Digital vasculitis in systemic lupus erythematosus: a minor manifestation of disease activity?. Lupus, 2009, 18, 990-993.	1.6	11
340	The possible role of physical exercise on the treatment of idiopathic inflammatory myopathies. Autoimmunity Reviews, 2009, 8, 355-359.	5.8	48
341	Metabolic syndrome in rheumatological diseases. Autoimmunity Reviews, 2009, 8, 415-419.	5.8	92
342	High frequency of lipoprotein risk levels for cardiovascular disease in Takayasu arteritis. Clinical Rheumatology, 2009, 28, 801-805.	2.2	20

#	Article	IF	CITATIONS
343	Vitamin D insufficiency: A risk factor to vertebral fractures in community-dwelling elderly women. Maturitas, 2009, 64, 218-222.	2.4	37
344	Juvenile onset systemic lupus erythematosus thyroid dysfunction: A subgroup with mild disease?. Journal of Autoimmunity, 2009, 33, 121-124.	6.5	13
345	Hiper-homocisteinemia e sÃndrome antifosfolÃpide primária. Revista Brasileira De Reumatologia, 2009, 49, 337-345.	0.8	2
346	III Consenso Brasileiro para Pesquisa de Autoanticorpos em Células HEp-2: perspectiva histórica, controle de qualidade e associaÁ§Ãµes clÃnicas. Jornal Brasileiro De Patologia E Medicina Laboratorial, 2009, 45, .	0.3	4
347	Macrophage activation syndrome associated with etanercept in a child with systemic onset juvenile idiopathic arthritis. Israel Medical Association Journal, 2009, $11$ , 635-6.	0.1	12
348	High-titer antichromatin antibody is associated with proliferative class IV of lupus nephritis. Clinical Rheumatology, 2008, 27, 1417-1421.	2.2	7
349	Quantifying subclinical central nervous lesions in primary antiphospholipid syndrome: The role of magnetization transfer imaging. Journal of Magnetic Resonance Imaging, 2008, 27, 483-488.	3.4	8
350	Effectiveness of medialâ€wedge insole treatment for valgus knee osteoarthritis. Arthritis and Rheumatism, 2008, 59, 603-608.	6.7	63
351	Systemic lupus erythematosus and "lupus dyslipoproteinemia― Autoimmunity Reviews, 2008, 7, 246-250.	5.8	81
352	Prevalence of depressive and anxiety disorders in systemic lupus erythematosus and their association with anti-ribosomal P antibodies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 695-700.	4.8	111
353	Osteoprotegerin/RANKL system imbalance in active polyarticularâ€onset juvenile idiopathic arthritis: a bone damage biomarker?. Scandinavian Journal of Rheumatology, 2008, 37, 439-444.	1.1	28
354	The influence of lean mass in trabecular and cortical bone in juvenile onset systemic lupus erythematosus. Lupus, 2008, 17, 787-792.	1.6	39
355	Autoimmune Orchitis., 2008,, 281-284.		8
356	Testicular Sertoli cell function in male systemic lupus erythematosus. Rheumatology, 2008, 47, 1692-1697.	1.9	64
357	Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus, 2008, 17, 596-604.	1.6	108
358	Consenso de lúpus eritematoso sistúmico. Revista Brasileira De Reumatologia, 2008, 48, 196-207.	0.8	35
359	Pregnancy outcome in juvenile systemic lupus erythematosus: a Brazilian multicenter cohort study. Journal of Rheumatology, 2008, 35, 1414-8.	2.0	27
360	Inflammatory cervicovaginal cytology is associated with disease activity in juvenile systemic lupus erythematosus. Lupus, 2007, 16, 430-435.	1.6	35

#	Article	IF	CITATIONS
361	Risk factors for amenorrhea in juvenile systemic lupus erythematosus (JSLE): a Brazilian multicentre cohort study. Lupus, 2007, 16, 531-536.	1.6	36
362	Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Lupus, 2007, 16, 239-244.	1.6	52
363	Capillaroscopy is a dynamic process in mixed connective tissue disease. Lupus, 2007, 16, 254-258.	1.6	54
364	Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus, 2007, 16, 350-354.	1.6	86
365	Antineutrophil Cytoplasmic Antibodies in Chronic Rhinosinusitis May be a Marker of Undisclosed Vasculitis. American Journal of Rhinology & Allergy, 2007, 21, 691-694.	2.2	9
366	Major depressive disorder and disease activity in systemic lupus erythematosus. Comprehensive Psychiatry, 2007, 48, 14-19.	3.1	121
367	Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus, 2007, 16, 273-278.	1.6	57
368	Gonad evaluation in male systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 2352-2361.	6.7	98
369	Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatology International, 2006, 26, 1078-1083.	3.0	21
370	Antibodies to ribosomal P proteins: A potential serologic marker for lupus membranous glomerulonephritis. Arthritis and Rheumatism, 2006, 54, 1568-1572.	6.7	55
371	Mechanisms of Dyslipoproteinemias in Systemic Lupus Erythematosus. Clinical and Developmental Immunology, 2006, 13, 203-208.	3.3	63
372	Endometriosis and Systemic Lupus Erythematosus: A Comparative Evaluation of Clinical Manifestations and Serological Autoimmune Phenomena. American Journal of Reproductive Immunology, 2005, 53, 85-93.	1,2	43
373	Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis and Rheumatism, 2005, 52, 1138-1147.	6.7	347
374	Lipoprotein profile in limited systemic sclerosis. Rheumatology International, 2005, 25, 379-383.	3.0	33
375	SÃndrome do lúpus neonatal. Revista Brasileira De Reumatologia, 2005, 45, 153.	0.8	3
376	Complement-fixing activity of anticardiolipin antibodies in patients with and without thrombosis. Lupus, 2005, 14, 953-958.	1.6	11
377	The frequency of high/moderate lipoprotein risk factor for coronary artery disease is significant in juvenile-onset systemic lupus erythematosus. Lupus, 2005, 14, 613-617.	1.6	11
378	Male systemic lupus erythematosus in a Latin-American inception cohort of 1214 patients. Lupus, 2005, 14, 938-946.	1.6	109

#	Article	IF	Citations
379	Avaliação dos fatores reprodutivos em 117 pacientes com esclerose sistêmica forma limitada e 72 pacientes com artrite reumatóide. Revista Brasileira De Reumatologia, 2005, 45, 114-118.	0.8	1
380	Desvendando a sÃndrome antifosfolÃpide catastrófica (sÃndrome de Asherson). Revista Brasileira De Reumatologia, 2005, 45, 374-381.	0.8	2
381	Lúpus eritematoso sistúmico: tratamento do acometimento cutâneo/articular. Revista Brasileira De Reumatologia, 2004, 44, 454-457.	0.8	1
382	Lúpus eritematoso sistêmico: tratamento do acometimento sistêmico. Revista Brasileira De Reumatologia, 2004, 44, 458-463.	0.8	4
383	Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry. Lupus, 2004, 13, 223-227.	1.6	45
384	FcÂRlla polymorphism: a susceptibility factor for immune complex-mediated lupus nephritis in Brazilian patients. Nephrology Dialysis Transplantation, 2004, 19, 1427-1431.	0.7	27
385	The GLADEL Multinational Latin American Prospective Inception Cohort of $1,214$ Patients With Systemic Lupus Erythematosus. Medicine (United States), 2004, 83, 1-17.	1.0	372
386	Is Isolated Congenital Heart Block Associated to Neonatal Lupus Requiring Pacemaker A Distinct Cardiac Syndrome?. PACE - Pacing and Clinical Electrophysiology, 2004, 27, 615-620.	1,2	18
387	Anti-lipoprotein lipase antibodies: A new player in the complex atherosclerotic process in systemic lupus erythematosus?. Arthritis and Rheumatism, 2004, 50, 3610-3615.	6.7	65
388	Myositis in mixed connective tissue disease: a unique syndrome characterized by immunohistopathologic elements of both polymyositis and dermatomyositis. Arquivos De Neuro-Psiquiatria, 2004, 62, 923-934.	0.8	24
389	II Consenso Brasileiro de Fator Antinuclear em Células HEp-2: Definitions for standardization of autoantibody testing against the nucleus (ANA HEp-2), nucleolus, cytoplasm and mitotic apparatus, as wel as its clinical associations. Revista Brasileira De Reumatologia, 2003, 43, 129-140.	0.8	32
390	Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus, 2002, 11, 175-180.	1.6	75
391	C-ANCA-positive IgG fraction from patients with Wegener's granulomatosis induces lung vasculitis in rats. Clinical and Experimental Immunology, 2002, 129, 54-60.	2.6	11
392	l Consenso Nacional para Padronização dos Laudos de FAN HEp-2. Jornal Brasileiro De Patologia E Medicina Laboratorial, 2002, 38, .	0.3	5
393	Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. Journal of Rheumatology, 2001, 28, 780-5.	2.0	97
394	Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis and Rheumatism, 2000, 43, 1033.	6.7	116
395	Eye disease in a patient with rheumatoid arthritis. Postgraduate Medical Journal, 1999, 75, 676-677.	1.8	11
396	Anti-corpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus?. Journal of Rheumatology, 1999, 26, 1087-93.	2.0	46

#	Article	IF	Citations
397	Induction of in vitro heart block is not restricted to affinity purified anti-52 kDa Ro/SSA antibody from mothers of children with neonatal lupus. Lupus, 1998, 7, 141-147.	1.6	30
398	Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus, 1997, 6, 533-539.	1.6	241
399	Ribosomal P Protein Autoantibodies. , 1996, , 721-726.		3
400	Antiribosomal Antibodies in SLE, Infection, and Following Deliberate Immunization. Advances in Experimental Medicine and Biology, 1994, 347, 81-92.	1.6	16
401	Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts Journal of Clinical Investigation, 1994, 93, 718-724.	8.2	135
402	Lipoprotein(a) levels in systemic lupus erythematosus. Journal of Rheumatology, 1994, 21, 220-3.	2.0	72
403	Autoantibodies in Chagas' disease. An antibody cross-reactive with human and Trypanosoma cruzi ribosomal proteins. Journal of Immunology, 1993, 150, 3917-23.	0.8	35
404	ANTIRIBOSOMAL ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS. Rheumatic Disease Clinics of North America, 1992, 18, 377-390.	1.9	50
405	Antiribosomal S10 antibodies in humans and MRL/lpr mice with systemic lupus erythematosus. Arthritis and Rheumatism, 1989, 32, 1252-1261.	6.7	39
406	Association between anti-Sm and anti-ribosomal P protein autoantibodies in human systemic lupus erythematosus and MRL/lpr mice. Journal of Immunology, 1989, 143, 1549-54.	0.8	55
407	Neonatal lupus risk to newborns of mothers with systemic lupus erythematosus. Arthritis and Rheumatism, 1988, 31, 697-701.	6.7	160
408	Detection of Immunoglobulin G Antibodies in Melanoma Sera Reactive with Intracellular Proteins. Journal of Investigative Dermatology, 1988, 90, 207-212.	0.7	13
409	Properties of the ribosomal P2 protein autoantigen are similar to those of foreign protein antigens Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 5186-5189.	7.1	82
410	Frequency and epitope recognition of anti-ribosome P antibodies from humans with systemic lupus erythematosus and MRL/lpr mice are similar. Journal of Immunology, 1988, 140, 3434-7.	0.8	27
411	Chronic active hepatitis associated with anti-liver-kidney microsome antibody type 1. Arquivos De Gastroenterologia, 1988, 25, 86-8.	0.8	0
412	Immunoblot analysis of IgG subclasses of multiple lupus autoantibodies. Journal of Immunology, 1988, 140, 2231-6.	0.8	29
413	Association between Lupus Psychosis and Antiribosomal P Protein Antibodies. New England Journal of Medicine, 1987, 317, 265-271.	27.0	554
414	Lupus anti-ribosomal P peptide antibodies show limited heterogeneity and are predominantly of the IgG1 and IgG2 subclasses. Clinical Immunology and Immunopathology, 1987, 45, 129-138.	2.0	28

#	Article	IF	CITATIONS
415	Characterization of autoantigens and autoantibodies by immunoblotting. Electrophoresis, 1987, 8, 445-451.	2.4	4
416	Ribosomal protein autoantibodies in systemic lupus erythematosus. BioEssays, 1987, 7, 258-261.	2.5	8
417	Comparison between autoantibodies in malaria and leprosy with lupus. Clinical and Experimental Immunology, 1987, 70, 529-37.	2.6	24
418	Clinical and serologic associations of the antiribosomal P protein antibody. Arthritis and Rheumatism, 1986, 29, 981-985.	6.7	146
419	Immunohistochemical localization of la nuclear antigen in brain. Journal of Neuroimmunology, 1985, 9, 307-319.	2.3	13
420	Incidence and risk factors for moderate/severe COVID-19 in rheumatic diseases patients on hydroxychloroquine: a 24-week prospective cohort. Clinical and Experimental Rheumatology, 0, , .	0.8	1